Annovis Bio Q2 loss widens as R&D costs rise
ANVS•Outlook
- Company expects top-line symptomatic data from Phase 3 Alzheimer's trial in Q1 2027
- Alzheimer's open-label extension study expected to initiate in October 2026
- Full enrollment for Parkinson's disease OLE study projected in Q4 2026
Overview
- US biotech firm's Q2 net loss per share widened yr/yr
- Company fully enrolled pivotal Phase 3 Alzheimer's trial, exceeding original target
- Q2 research and development expenses more than doubled from a year earlier
Result drivers and key details
- Trial enrollment - Co fully enrolled pivotal Phase 3 Alzheimer's trial with 850 patients, exceeding original target
- Higher R&D spending - Research and development expenses more than doubled yr/yr as company advanced clinical programs
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Loss Per Share | $0.40 |
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell". The average consensus recommendation for the biotechnology & medical research peer group is "buy". Wall Street's median 12-month price target for Annovis Bio Inc is $10.00, about 458.7% above its August 13 closing price of $1.79.
